VSEE HEALTH, INC. (VSEE): Completion of Acquisition or Disposition of Assets
VSEE HEALTH, INC. (VSEE) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-99.1 3 vseeex99-1.htm EXHIBIT 99.1 Exhibit 99.1 VSEE HEALTH, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS On May 31, 2026, VSee Health, Inc., a Delaware corporation (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with
How this was made
The 30-second read
Why it matters
Completion of the disposition changes consolidated financial statement composition and removes VSee Lab revenues/costs from the pro forma presentation; retained liabilities and tax responsibility for pre-closing periods may offset any balance-sheet simplification.
Market read
Traders should reassess VSEE’s post-transaction earnings power and liability exposure given the divestiture and the pro forma balance sheet/operations adjustments.
What to watch
Key risk is the liability allocation: the company retains pre-closing liabilities (including certain taxes), while Chen is responsible for specific unpaid liabilities at closing—details could drive valuation more than the pro forma headline.
Background
VSee Health entered a Stock Purchase Agreement on May 31, 2026 to sell all equity of its wholly owned subsidiary VSee Lab to Milton Chen, with closing on May 31 and related executive changes effective at closing.
Ticker impact
VSee Health completed a stock purchase/disposition of its wholly owned VSee Lab, with Milton Chen buying the subsidiary’s equity and Chen resigning as co-CEO/chair at closing.
Likely choppy/uncertain trading as investors digest the subsidiary divestiture, liability retention/assumption terms, and resulting earnings power.
The filing is a primary SEC 8-K completion disclosure, but the excerpt provides pro forma balance sheet/statement mechanics without explicit deal consideration or forward guidance, limiting precision on earnings impact.
Market effects
Limited direct read-across; this is company-specific corporate restructuring rather than a sector-wide signal.
No clear regional spillover indicated in the filing excerpt.
No global macro or cross-border market linkage described.
Counterpoint
Investors may view the deal as a clean separation that reduces consolidated liabilities and improves focus, despite the apparent earnings volatility.
Key entities
- CompanyVSEE Health, Inc.
Issuer filing the 8-K; completed disposition of VSee Lab equity to Milton Chen.
- SubsidiaryVSee Lab, Inc.
Wholly owned subsidiary whose equity was sold to Milton Chen at closing.
- PersonMilton Chen
Co-CEO/chair and CEO of VSee Lab; purchased VSee Lab equity and resigned from VSee roles effective at closing.
